Amarin Corp Plc (AMRN)

[ziploc_1]

QUOTE..."R. Preston Mason, MBA, PhD, is on the faculty of the Department of Medicine, Division of Cardiology, at the Harvard Medical School-affiliated Brigham and Women's Hospital in Boston, Massachusetts."

If Dr. Mason's studies demonstrate that generic "fake Vascepa" capsules have less EPA than branded Vascepa capsules, it becomes incumbent on the generic companies to undertake studies of their own to prove that Dr. Mason's studies were flawed...Until the generic companies can prove that Dr. Mason's findings were incorrect...the FDA should halt the sale of gV.

In the meantime the generics have NO studies to show that their inferior capsulation of EPA does not matter in the effectiveness in reducing CVD

GENERIC V IS NOT BIOSIMILAR TO VASCEPA!!